Cyrus P Zabetian

List of Publications by Citations

133 papers	10,082 citations	53 h-index	99 g-index
141 ext. papers	11,838 ext. citations	7.2 avg, IF	5.33 L-index

#	Paper	IF	Citations
133	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurology, The*, **2008**, 7, 583-90	24.1	1075
132	Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. *Nature Genetics*, **2010**, 42, 781-5	36.3	574
131	DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. *Brain*, **2010**, 133, 713-26	11.2	483
130	Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. *PLoS Genetics*, **2012**, 8, e1002548	6	420
129	Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. *Movement Disorders*, **2017**, 32, 739-749	7	405
128	Plasma exosomal -synuclein is likely CNS-derived and increased in Parkinson's disease. *Acta Neuropathologica*, **2014**, 128, 639-650	14.3	348
127	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. *Annals of Neurology*, **2011**, 69, 570-80	9.4	310
126	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurology, The*, **2017**, 16, 55-65	24.1	273
125	APOE 4 increases risk for dementia in pure synucleinopathies. *JAMA Neurology*, **2013**, 70, 223-8	17.2	243
124	A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. *American Journal of Human Genetics*, **2001**, 68, 515-22	11	231
123	Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. *Annals of Neurology*, **2012** , 71, 370-84	9.4	214
122	Phosphorylated -synuclein in Parkinson's disease. *Science Translational Medicine*, **2012**, 4, 121ra20	17.5	182
121	Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. *PLoS Genetics*, **2011**, 7, e1002237	6	163
120	Salivary -synuclein and DJ-1: potential biomarkers for Parkinson's disease. *Brain*, **2011**, 134, e178	11.2	162
119	Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. *Neuroscience Letters*, **2010**, 480, 78-82	3.3	146
118	Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. *Archives of Neurology*, **2008**, 65, 379-82		146
117	APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. *JAMA Neurology*, **2014**, 71, 1405-12	17.2	135

116	CSF A(1-42) and tau in Parkinson's disease with cognitive impairment. *Movement Disorders*, **2010**, 25, 2682-5	7	132
115	SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. *Archives of Neurology*, **2010**, 67, 1350-6		129
114	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. *JAMA Neurology*, **2016**, 73, 1217-1224	17.2	120
113	Association of Parkinson disease with structural and regulatory variants in the HLA region. *American Journal of Human Genetics*, **2013**, 93, 984-93	11	116
112	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. *Movement Disorders*, **2016**, 31, 95-102	7	113
111	GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. *Neurology*, **2012**, 79, 1944-50	6.5	113
110	Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. *Movement Disorders*, **2008**, 23, 88-95	7	113
109	Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. *Annals of Neurology*, **2007**, 62, 137-44	9.4	108
108	LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. *American Journal of Human Genetics*, **2006**, 79, 752-8	11	99
107	CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. *Alzheimer's and Dementia*, **2016**, 12, 1125-1131	1.2	99
106	Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. *Annals of Neurology*, **2007**, 61, 47-54	9.4	96
105	Plasma apolipoprotein A1 as a biomarker for Parkinson disease. *Annals of Neurology*, **2013**, 74, 119-27	9.4	90
104	Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). *Human Molecular Genetics*, **2013**, 22, 3259-68	5.6	89
103	Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. *JAMA Neurology*, **2013**, 70, 852-8	17.2	87
102	Exploring gene-environment interactions in Parkinson's disease. *Human Genetics*, **2008**, 123, 257-65	6.3	83
101	Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. *Lancet Neurology, The*, **2006**, 5, 917-23	24.1	80
100	Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. *Movement Disorders*, **2018**, 33, 793-804	7	77
99	Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. *American Journal of Pathology*, **2011**, 178, 1509-16	5.8	77

98	Mutations in the dopamine β-hydroxylase gene are associated with human norepinephrine deficiency. *American Journal of Medical Genetics Part A*, **2002**, 108, 140-147		76
97	The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. *American Journal of Human Genetics*, **2003**, 72, 1389-400	11	76
96	Glycoproteomics in neurodegenerative diseases. *Mass Spectrometry Reviews*, **2010**, 29, 79-125	11	75
95	Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. *Archives of Neurology*, **2006**, 63, 1250-4		75
94	New windows into the brain: Central nervous system-derived extracellular vesicles in blood. *Progress in Neurobiology*, **2019**, 175, 96-106	10.9	70
93	Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. *Movement Disorders*, **2006**, 21, 519-23	7	70
92	Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 564-8	5.5	69
91	A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. *Biological Psychiatry*, **2002**, 52, 1151-8	7.9	68
90	Sigma receptors are associated with cortical limbic areas in the primate brain. *Synapse*, **1992**, 12, 195-205	2.4	67
89	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. *Lancet Neurology, The*, **2017**, 16, 351-359	24.1	64
88	Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. *Movement Disorders*, **2005**, 20, 1077-8	7	64
87	Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. *Npj Parkinson's Disease*, **2020**, 6, 11	9.7	62
86	Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. *American Journal of Epidemiology*, **2009**, 170, 1344-57	3.8	61
85	Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. *Journal of Proteome Research*, **2008**, 7, 720-30	5.6	59
84	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 50, 29-36	3.6	56
83	Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. *Movement Disorders*, **2011**, 26, 819-23	7	55
82	Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. *Parkinsonism and Related Disorders*, **2011**, 17, 61-4	3.6	54
81	Genetic association between alpha-synuclein and idiopathic Parkinson's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2008**, 147B, 1222-30	3.5	54

80	Phosphorylated □synuclein in Parkinson's disease: correlation depends on disease severity. *Acta Neuropathologica Communications*, **2015**, 3, 7	7.3	53
79	Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. *Journal of Parkinsons Disease*, **2013**, 3, 205-14	5.3	51
78	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. *Movement Disorders*, **2014**, 29, 1258-64	7	50
77	Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. *Biological Psychiatry*, **2002**, 51, 358-64	7.9	49
76	Evaluation of mild cognitive impairment subtypes in Parkinson's disease. *Movement Disorders*, **2014** , 29, 756-64	7	48
75	LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. *Movement Disorders*, **2009**, 24, 1034-41	7	48
74	Evidence for more than one Parkinson's disease-associated variant within the HLA region. *PLoS ONE*, **2011**, 6, e27109	3.7	47
73	Identification of a novel Parkinson's disease locus via stratified genome-wide association study. *BMC Genomics*, **2014**, 15, 118	4.5	45
72	Effects of environmental salinity on pituitary growth hormone content and cell activity in the euryhaline tilapia, Oreochromis mossambicus. *General and Comparative Endocrinology*, **1994**, 95, 483-94	3	44
71	Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. *Movement Disorders*, **2011**, 26, 2190-5	7	43
70	Arguing against the proposed definition changes of PD. *Movement Disorders*, **2016**, 31, 1619-1622	7	43
69	Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. *Molecular and Cellular Proteomics*, **2015**, 14, 544-55	7.6	42
68	A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms. *Biological Psychiatry*, **2006**, 60, 1034-8	7.9	40
67	Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans. *European Journal of Human Genetics*, **2007**, 15, 878-83	5.3	39
66	Identification of genetic modifiers of age-at-onset for familial Parkinson's disease. *Human Molecular Genetics*, **2016**, 25, 3849-3862	5.6	37
65	The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. *Lancet Neurology, The*, **2018**, 17, 309-316	24.1	35
64	Precision Medicine: Clarity for the Complexity of Dementia. *American Journal of Pathology*, **2016**, 186, 500-6	5.8	32
63	Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. *Neurogenetics*, **2009**, 10, 347-53	3	32

62	DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. *Neurobiology of Aging*, **2012**, 33, 836.e5-7	5.6	31
61	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. *Movement Disorders*, **2015**, 30, 805-12	7	29
60	Haplotype-controlled analysis of the association of a non-synonymous single nucleotide polymorphism at DBH (+ 1603C --> T) with plasma dopamine beta-hydroxylase activity. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2005**, 139B, 88-90	3.5	29
59	Homocysteine and cognitive function in Parkinson's disease. *Parkinsonism and Related Disorders*, **2017**, 44, 1-5	3.6	28
58	Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. *Parkinsonism and Related Disorders*, **2009**, 15, 466-7	3.6	28
57	LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. *Parkinsonism and Related Disorders*, **2009**, 15, 370-3	3.6	28
56	Targeted discovery and validation of plasma biomarkers of Parkinson's disease. *Journal of Proteome Research*, **2014**, 13, 4535-45	5.6	25
55	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. *Neurobiology of Aging*, **2017**, 56, 211.e1-211.e7	5.6	24
54	Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease. *Parkinsonism and Related Disorders*, **2019**, 69, 104-110	3.6	24
53	Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control. *Neurobiology of Aging*, **2014**, 35, 418-20	5.6	24
52	Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease. *European Journal of Neurology*, **2008**, 15, 134-9	6	24
51	Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. *Alzheimer's and Dementia*, **2013**, 9, 609-14	1.2	22
50	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. *Movement Disorders*, **2018**, 33, 1750-1759	7	22
49	Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised. *Arquivos De Neuro-Psiquiatria*, **2015**, 73, 929-33	1.6	21
48	The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. *Parkinsonism and Related Disorders*, **2019**, 63, 204-208	3.6	20
47	Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk. *Parkinsonism and Related Disorders*, **2015**, 21, 1087-92	3.6	19
46	LARGE-PD: Examining the genetics of Parkinson's disease in Latin America. *Movement Disorders*, **2017**, 32, 1330-1331	7	19
45	Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. *Neurogenetics*, **2009**, 10, 355-8	3	19

44	Osteology and Interrelationships of the Sand Lances (Teleostei: Ammodytidae). *Copeia*, **1990**, 1990, 78	1.1	19
43	C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. *JAMA Neurology*, **2013**, 70, 742-5	17.2	18
42	Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease. *Neurobiology of Aging*, **2014**, 35, 2656.e17-2656.e23	5.6	17
41	[3H]-(+)-pentazocine binding to sigma recognition sites in human cerebellum. *Life Sciences*, **1994**, 55, PL389-95	6.8	17
40	Variable frequency of variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry. *Npj Parkinson's Disease*, **2017**, 3, 19	9.7	16
39	A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics. *Parkinsonism and Related Disorders*, **2015**, 21, 444-8	3.6	16
38	A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity. *Movement Disorders*, **2010** , 25, 1409-17	7	16
37	Analysis of the LRRK2 G2019S mutation in Alzheimer Disease. *Archives of Neurology*, **2006**, 63, 156-7		16
36	Erythrocytic □synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis. *Acta Neuropathologica Communications*, **2020**, 8, 102	7.3	14
35	Functional variants at CYP2A6: new genotyping methods, population genetics, and relevance to studies of tobacco dependence. *American Journal of Medical Genetics Part A*, **2000**, 96, 638-45		14
34	Association mapping of the PARK10 region for Parkinson's disease susceptibility genes. *Parkinsonism and Related Disorders*, **2014**, 20, 93-8	3.6	13
33	Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. *Genetic Testing and Molecular Biomarkers*, **2006**, 10, 221-7		13
32	Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. *Movement Disorders*, **2012**, 27, 1822-5	7	12
31	Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America. *Parkinsonism and Related Disorders*, **2011**, 17, 629-31	3.6	12
30	The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2016**, 171, 925-30	3.5	11
29	Variations in the dopamine beta-hydroxylase gene are not associated with the autonomic disorders, pure autonomic failure, or multiple system atrophy. *American Journal of Medical Genetics Part A*, **2003**, 120A, 234-6		11
28	Multivariate prediction of dementia in Parkinson's disease. *Npj Parkinson's Disease*, **2020**, 6, 20	9.7	10
27	Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease. *Dementia E Neuropsychologia*, **2016**, 10, 333-338	2.1	10

26	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Annals of Neurology*, **2021**, 90, 76-88	9.4	9
25	Plasticity-related gene 3 () and age at diagnosis of Parkinson disease. *Neurology: Genetics*, **2018**, 4, e271	3.8	9
24	A revised allele frequency estimate and haplotype analysis of the DBH deficiency mutation IVS1+2T --> C in African- and European-Americans **2003**, 123A, 190-2		8
23	Characterizing the Genetic Architecture of Parkinson's Disease in Latinos. *Annals of Neurology*, **2021**, 90, 353-365	9.4	8
22	Glutamate receptor gene GRIN2A, coffee, and Parkinson disease. *PLoS Genetics*, **2014**, 10, e1004774	6	7
21	Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry. *Parkinson's Disease*, **2018**, 2018, 3719578	2.6	7
20	Intrafamilial variable phenotype including corticobasal syndrome in a family with p.P301L mutation in the MAPT gene: first report in South America. *Neurobiology of Aging*, **2017**, 53, 195.e11-195.e17	5.6	6
19	Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease. *Genetic Epidemiology*, **2010**, 34, 92-9	2.6	6
18	Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease. *Nitric Oxide - Biology and Chemistry*, **2018**, 74, 86-90	5	5
17	The UCHL1 S18Y polymorphism and Parkinson's disease in a Japanese population. *Parkinsonism and Related Disorders*, **2011**, 17, 473-5	3.6	5
16	DBH -1021C-->T does not modify risk or age at onset in Parkinson's disease. *Annals of Neurology*, **2007**, 62, 99-101	9.4	5
15	Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease. *Arquivos De Neuro-Psiquiatria*, **2020**, 78, 206-216	1.6	5
14	Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients. *Movement Disorders*, **2021**, 36, 434-441	7	4
13	Exploring human-genome gut-microbiome interaction in Parkinson's disease. *Npj Parkinson's Disease*, **2021**, 7, 74	9.7	4
12	Characterizing dysbiosis of gut microbiome in PD: Evidence for overabundance of opportunistic pathogens		3
11	Response to the letter "Haptoglobin phenotype and Parkinson disease risk" by Delanghe et al. *Parkinsonism and Related Disorders*, **2016**, 22, 110-1	3.6	3
10	Novel compound heterozygous FBXO7 mutations in a family with early onset Parkinson's disease. *Parkinsonism and Related Disorders*, **2020**, 80, 142-147	3.6	2
9	Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying Synuclein-Containing Extracellular Vesicles. *Neurology*, **2021**, 96, e2332-e2345	6.5	2

8	Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease. *Journal of Clinical and Experimental Neuropsychology*, **2021**, 43, 469-480	2.1	2
7	Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain. *Movement Disorders*, **2013**, 28, 248	7	1
6	Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis. *Archives of Neurology*, **2009**, 66, 280-1		1
5	Characterizing the genetic architecture of Parkinson disease in Latinos		1
4	Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease. *Frontiers in Neurology*, **2020**, 11, 893	4.1	1
3	Human-genome gut-microbiome interaction in Parkinson disease		1
2	Relationships Between Sensorimotor Inhibition and Mobility in Older Adults With and Without Parkinson's Disease. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, 630-637	6.4	0
1	Molecular Genetic Analysis of Plasma Dopamine Hydroxylase in Depression. *Advances in Behavioral Biology*, **2002**, 423-426		